Here’s what you should know.
1. Bloomberg is calling the Shire acquisition, “the best thing that could have happened to the Japanese drugmaker.”
2. Shire allows Takeda a pathway into the U.S.
Bloomberg said the only other way Takeda could’ve got such exposure was if it acquired either Celgene Corp. or Biogen. Both companies would’ve set Takeda back a considerable amount more than the $62 billion Shire was acquired for.
3. Although Shire has the potential to strain Takeda’s budget without realizing many short-term returns, Shire significantly boosts Takeda’s presence in the rare disease drugs market which has a massive amount of cash flow.
4. The acquisition is not without its risks, but “maybe, in taking a risk, Takeda will cement its place in the global pharmaceuticals market. With its stock rallying as much as 3.7 percent [May 10], it seems some shareholders at least share the view that in Shire, Takeda has found the savior it sorely needed.”
More articles on supply chain:
California bill allowing government to determine healthcare pricing met with fierce opposition
Common deficiencies cited by AAAASF and how to fix them — Every OR must be equipped with an AED or standard defibrillator
Total joints in ASCs: 4 common questions answered
